CN100463921C - 白蛋白纯化 - Google Patents
白蛋白纯化 Download PDFInfo
- Publication number
- CN100463921C CN100463921C CNB031235026A CN03123502A CN100463921C CN 100463921 C CN100463921 C CN 100463921C CN B031235026 A CNB031235026 A CN B031235026A CN 03123502 A CN03123502 A CN 03123502A CN 100463921 C CN100463921 C CN 100463921C
- Authority
- CN
- China
- Prior art keywords
- medium
- aglucon
- fermented liquid
- rhsa
- hydrophobic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000009027 Albumins Human genes 0.000 title claims abstract description 15
- 108010088751 Albumins Proteins 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 56
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 239000007788 liquid Substances 0.000 claims abstract description 25
- 239000006228 supernatant Substances 0.000 claims abstract description 25
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 12
- 230000002829 reductive effect Effects 0.000 claims abstract description 9
- 238000011210 chromatographic step Methods 0.000 claims abstract description 6
- 239000002609 medium Substances 0.000 claims description 58
- 230000005611 electricity Effects 0.000 claims description 12
- 125000000129 anionic group Chemical group 0.000 claims description 11
- 238000005341 cation exchange Methods 0.000 claims description 9
- 239000003292 glue Substances 0.000 claims description 9
- 230000003993 interaction Effects 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 238000005571 anion exchange chromatography Methods 0.000 claims description 5
- 239000012501 chromatography medium Substances 0.000 claims description 5
- 238000005277 cation exchange chromatography Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 238000002086 displacement chromatography Methods 0.000 claims 4
- 230000001588 bifunctional effect Effects 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 abstract description 12
- -1 salt cation Chemical class 0.000 abstract description 11
- 238000000746 purification Methods 0.000 abstract description 6
- 239000000523 sample Substances 0.000 description 29
- 239000011159 matrix material Substances 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000012530 fluid Substances 0.000 description 14
- 238000013016 damping Methods 0.000 description 12
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 239000008367 deionised water Substances 0.000 description 10
- 229910021641 deionized water Inorganic materials 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 108091006905 Human Serum Albumin Proteins 0.000 description 9
- 102000008100 Human Serum Albumin Human genes 0.000 description 9
- 229920002684 Sepharose Polymers 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 9
- 239000012535 impurity Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 8
- 229920000936 Agarose Polymers 0.000 description 8
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 6
- 239000012619 Butyl Sepharose® Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 229910052709 silver Inorganic materials 0.000 description 5
- 239000004332 silver Substances 0.000 description 5
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 229920002271 DEAE-Sepharose Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 229910010272 inorganic material Inorganic materials 0.000 description 4
- 239000011147 inorganic material Substances 0.000 description 4
- 239000011368 organic material Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 235000019800 disodium phosphate Nutrition 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 235000011008 sodium phosphates Nutrition 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 150000003009 phosphonic acids Chemical class 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 229960004249 sodium acetate Drugs 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 238000007669 thermal treatment Methods 0.000 description 2
- JHPBZFOKBAGZBL-UHFFFAOYSA-N (3-hydroxy-2,2,4-trimethylpentyl) 2-methylprop-2-enoate Chemical compound CC(C)C(O)C(C)(C)COC(=O)C(C)=C JHPBZFOKBAGZBL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
- 229910052728 basic metal Inorganic materials 0.000 description 1
- 150000003818 basic metals Chemical class 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000012504 chromatography matrix Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical group O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- BPUBBGLMJRNUCC-UHFFFAOYSA-N oxygen(2-);tantalum(5+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Ta+5].[Ta+5] BPUBBGLMJRNUCC-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229910001936 tantalum oxide Inorganic materials 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201518A SE526227C2 (sv) | 2002-05-15 | 2002-05-15 | Metod för rening av rekombinant humant serumalbumin |
| SE02015188 | 2002-05-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1496993A CN1496993A (zh) | 2004-05-19 |
| CN100463921C true CN100463921C (zh) | 2009-02-25 |
Family
ID=20287916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031235026A Expired - Fee Related CN100463921C (zh) | 2002-05-15 | 2003-05-09 | 白蛋白纯化 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7423124B2 (OSRAM) |
| EP (2) | EP1504031B1 (OSRAM) |
| JP (2) | JP2006502098A (OSRAM) |
| CN (1) | CN100463921C (OSRAM) |
| AT (1) | ATE335006T1 (OSRAM) |
| AU (2) | AU2003228193B2 (OSRAM) |
| BR (2) | BRPI0309992B1 (OSRAM) |
| CA (2) | CA2483612A1 (OSRAM) |
| DE (1) | DE60307262T2 (OSRAM) |
| ES (1) | ES2268362T3 (OSRAM) |
| IL (1) | IL164844A (OSRAM) |
| SE (1) | SE526227C2 (OSRAM) |
| WO (2) | WO2003097692A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8802146B2 (en) * | 1998-11-06 | 2014-08-12 | Neomend, Inc. | Systems, methods, and compositions for prevention of tissue adhesion |
| VN23181A1 (en) * | 2003-01-28 | 2010-07-26 | Du Pont | Cyano anthranilamide insecticides |
| WO2004080575A1 (en) * | 2003-03-12 | 2004-09-23 | Fresenius Kabi Deutschland Gmbh | Use of recombinant albumin in dialysis after liver failure |
| CA2564031A1 (en) * | 2004-04-23 | 2005-11-03 | Conjuchem Biotechnologies Inc. | Method for the purification of albumin conjugates |
| CN1854155B (zh) * | 2005-04-29 | 2010-11-17 | 华北制药集团新药研究开发有限责任公司 | 一种纯化rHSA的方法 |
| CL2008002054A1 (es) * | 2007-07-17 | 2009-05-29 | Hoffmann La Roche | Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico. |
| CL2008002053A1 (es) * | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion. |
| CN101978268B (zh) * | 2008-03-31 | 2014-04-23 | 积水医疗株式会社 | 纯化血清白蛋白及免疫学测定方法 |
| US8753868B2 (en) | 2008-08-04 | 2014-06-17 | General Electric Company | Method and system for selective isolation of target biological molecules in a general purpose system |
| CN101768206B (zh) * | 2008-12-31 | 2013-05-15 | 华北制药集团新药研究开发有限责任公司 | 一种重组人血清白蛋白的纯化方法及其应用 |
| WO2010096588A2 (en) | 2009-02-20 | 2010-08-26 | Ventria Bioscience | Cell culture media containing combinations of proteins |
| EP4492053A3 (en) * | 2010-05-25 | 2025-03-19 | F. Hoffmann-La Roche AG | Methods of purifying polypeptides |
| CN102127164B (zh) | 2010-12-20 | 2013-01-30 | 武汉禾元生物科技有限公司 | 一种从水稻种子中提取重组人血清白蛋白的方法 |
| CN102532254B (zh) * | 2010-12-24 | 2015-06-24 | 武汉禾元生物科技股份有限公司 | 一种从水稻种子中分离纯化重组人血清白蛋白的方法 |
| WO2013134251A2 (en) * | 2012-03-08 | 2013-09-12 | Bio-Rad Laboratories, Inc. | Anionic exchange-hydrophobic mixed mode |
| CN103880947B (zh) | 2012-12-21 | 2016-01-13 | 武汉禾元生物科技股份有限公司 | 一种分离纯化高纯度重组人血清白蛋白的层析方法 |
| CN103923211A (zh) * | 2014-05-08 | 2014-07-16 | 齐智 | 一种医药级重组人血清白蛋白的纯化方法 |
| CN107709552B (zh) * | 2015-06-10 | 2022-05-13 | 南克维斯特公司 | 用于治疗癌症的修饰的nk-92细胞 |
| CN106146631A (zh) * | 2015-12-09 | 2016-11-23 | 烟台大学 | 一种离心技术结合疏水层析介质制备藻红蛋白的方法 |
| CN106117326A (zh) * | 2015-12-09 | 2016-11-16 | 烟台大学 | 一种离心法结合阴离子交换层析介质制备藻红蛋白的方法 |
| CN106117347A (zh) * | 2015-12-09 | 2016-11-16 | 烟台大学 | 一种疏水层析制备高纯度藻红蛋白的方法 |
| IL291020B2 (en) * | 2019-09-24 | 2025-04-01 | Regeneron Pharma | Systems and methods for use in chromatography and regeneration |
| US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
| US12161777B2 (en) | 2020-07-02 | 2024-12-10 | Davol Inc. | Flowable hemostatic suspension |
| JP7674630B2 (ja) | 2020-12-08 | 2025-05-12 | 通化安睿特生物製薬股▲フェン▼有限公司 | 組換えタンパク質を精製する方法 |
| CN116744984A (zh) | 2020-12-28 | 2023-09-12 | 达沃有限公司 | 包含蛋白质和多官能化改性的基于聚乙二醇的交联剂的反应性干粉状止血材料 |
| CN113461804A (zh) * | 2021-08-09 | 2021-10-01 | 山东健通生物科技有限公司 | 减少重组人血白蛋白发酵过程中色素的方法 |
| CN113880908B (zh) * | 2021-08-25 | 2024-05-14 | 北京伟德杰生物科技有限公司 | 纯化重组人血清白蛋白的融合蛋白的方法 |
| CN113735962B (zh) * | 2021-08-27 | 2023-11-10 | 常熟纳微生物科技有限公司 | 一种从猪血中纯化重组人血清白蛋白的方法及应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5986062A (en) * | 1992-05-20 | 1999-11-16 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4093612A (en) * | 1975-08-04 | 1978-06-06 | Research Corporation | Selective removal of albumin from blood fluids and compositions therefore |
| FR2403098A1 (fr) * | 1977-09-19 | 1979-04-13 | Merieux Inst | Nouveau materiau capable de fixer de facon reversible des macromolecules biologiques, sa preparation et son application |
| JPH06501033A (ja) * | 1991-07-12 | 1994-01-27 | ギスト ブロカデス ナムローゼ フェンノートシャップ | 血清アルブミンの精製方法 |
| US5849874A (en) * | 1991-07-12 | 1998-12-15 | Gist-Brocades, N.V. | Process for the purification of serum albumin |
| JPH07102148B2 (ja) * | 1992-05-20 | 1995-11-08 | 株式会社ミドリ十字 | 遺伝子操作により得られるヒト血清アルブミンの製造方法、およびそれにより得られるヒト血清アルブミン含有組成物 |
| US5440018A (en) * | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
| CA2116385A1 (en) | 1993-02-25 | 1994-08-26 | Akinori Sumi | Human serum albumin and process for producing the same |
| DE69434126T3 (de) * | 1993-12-17 | 2009-07-09 | Mitsubishi Pharma Corp. | Verfahren zum Entfärben von menschlichemn Serum-Albumin |
| CA2157219C (en) * | 1994-08-31 | 2010-10-05 | Munehiro Noda | Process for purifying recombinant human serum albumin |
| JP3840674B2 (ja) * | 1994-08-31 | 2006-11-01 | 三菱ウェルファーマ株式会社 | 遺伝子操作に由来するヒト血清アルブミンの精製方法 |
| GB9902000D0 (en) * | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
| SE0002688D0 (sv) * | 2000-07-17 | 2000-07-17 | Amersham Pharm Biotech Ab | Adsorption method and ligands |
| JP4798832B2 (ja) * | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | ヒト血清アルブミン多量体の除去方法 |
-
2002
- 2002-05-15 SE SE0201518A patent/SE526227C2/sv not_active IP Right Cessation
-
2003
- 2003-05-09 CN CNB031235026A patent/CN100463921C/zh not_active Expired - Fee Related
- 2003-05-09 EP EP03725953A patent/EP1504031B1/en not_active Expired - Lifetime
- 2003-05-09 BR BRPI0309992-0A patent/BRPI0309992B1/pt active IP Right Grant
- 2003-05-09 US US10/514,536 patent/US7423124B2/en not_active Expired - Lifetime
- 2003-05-09 DE DE60307262T patent/DE60307262T2/de not_active Expired - Lifetime
- 2003-05-09 WO PCT/SE2003/000766 patent/WO2003097692A1/en not_active Ceased
- 2003-05-09 AT AT03725953T patent/ATE335006T1/de not_active IP Right Cessation
- 2003-05-09 ES ES03725953T patent/ES2268362T3/es not_active Expired - Lifetime
- 2003-05-09 JP JP2004506364A patent/JP2006502098A/ja active Pending
- 2003-05-09 AU AU2003228193A patent/AU2003228193B2/en not_active Ceased
- 2003-05-09 CA CA002483612A patent/CA2483612A1/en not_active Abandoned
- 2003-05-09 BR BRPI0309992A patent/BRPI0309992B8/pt active IP Right Grant
- 2003-05-15 EP EP03752962A patent/EP1504032A1/en not_active Withdrawn
- 2003-05-15 JP JP2004506365A patent/JP4559216B2/ja not_active Expired - Fee Related
- 2003-05-15 WO PCT/SE2003/000792 patent/WO2003097693A1/en not_active Ceased
- 2003-05-15 AU AU2003232704A patent/AU2003232704A1/en not_active Abandoned
- 2003-05-15 US US10/514,544 patent/US7351801B2/en not_active Expired - Fee Related
- 2003-05-15 CA CA002483616A patent/CA2483616A1/en not_active Abandoned
-
2004
- 2004-10-26 IL IL164844A patent/IL164844A/en not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5986062A (en) * | 1992-05-20 | 1999-11-16 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| DE60307262D1 (de) | 2006-09-14 |
| AU2003228193A1 (en) | 2003-12-02 |
| ATE335006T1 (de) | 2006-08-15 |
| JP2006512283A (ja) | 2006-04-13 |
| JP2006502098A (ja) | 2006-01-19 |
| US7351801B2 (en) | 2008-04-01 |
| EP1504032A1 (en) | 2005-02-09 |
| SE0201518D0 (sv) | 2002-05-15 |
| WO2003097693A1 (en) | 2003-11-27 |
| JP4559216B2 (ja) | 2010-10-06 |
| EP1504031A1 (en) | 2005-02-09 |
| US20050215765A1 (en) | 2005-09-29 |
| SE526227C2 (sv) | 2005-08-02 |
| EP1504031B1 (en) | 2006-08-02 |
| US7423124B2 (en) | 2008-09-09 |
| CA2483616A1 (en) | 2003-11-27 |
| CA2483612A1 (en) | 2003-11-27 |
| AU2003232704A1 (en) | 2003-12-02 |
| BRPI0309992B1 (pt) | 2020-12-22 |
| BRPI0309992B8 (pt) | 2023-03-21 |
| AU2003228193B2 (en) | 2009-05-07 |
| ES2268362T3 (es) | 2007-03-16 |
| DE60307262T2 (de) | 2007-06-28 |
| BR0309992A (pt) | 2005-03-01 |
| IL164844A (en) | 2009-09-01 |
| IL164844A0 (en) | 2005-12-18 |
| US20050214902A1 (en) | 2005-09-29 |
| WO2003097692A1 (en) | 2003-11-27 |
| CN1496993A (zh) | 2004-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1496993A (zh) | 白蛋白纯化 | |
| US4673734A (en) | Porous mineral support coated with an aminated polysaccharide polymer | |
| Ostrove | [29] Affinity chromatography: General methods | |
| CA2157219A1 (en) | Process for purifying recombinant human serum albumin | |
| US5234991A (en) | Porous mineral support coated with an aminated polysaccharide polymer | |
| CN101260145A (zh) | 一种重组人血清白蛋白及其融合蛋白的分离纯化工艺 | |
| Safarik et al. | Magnetic cation exchange isolation of lysozyme from native hen egg white | |
| Harshman et al. | [1] Preparation and purification of staphylococcal alpha toxin | |
| KR920009730B1 (ko) | 백일해 성분 백신 및 백일해 항원, 디프테리아 톡소이드 및 파상풍 톡소이드의 혼합백신의 제조방법 | |
| US5045203A (en) | Separation of protein antigens of Bordetella bacteria by affinity chromatography | |
| US6555661B1 (en) | Simple, environmentally benign, method for purifying protein A | |
| CN101250512B (zh) | 内切木聚糖酶的仿生亲和纯化方法 | |
| CN111871396A (zh) | 一种白蛋白静电亲和双模式层析介质及其制备方法和应用 | |
| WO1995029187A1 (en) | Chromatographic process for the copurification of chondroitinase i and ii proteins | |
| KR890001069B1 (ko) | B형 간염 항원의 정제방법 | |
| Scott et al. | Affinity chromatography purification of Clostridium perfringens enterotoxin | |
| EP0868507B1 (en) | Process for the purification of urease from helicobacter pylori | |
| RU2036236C1 (ru) | Способ очистки щелочной фосфатазы из тонкого кишечника тюленя | |
| WO1991013976A1 (fr) | Procede pour la production d'un activateur plasminogene de tissus purifie ou de ses derives | |
| CN119709869A (zh) | 一种腺相关病毒载体的纯化方法 | |
| Cruz et al. | Preparative isolation of recombinant human insulin-A chain by ion exchange chromatography | |
| KR20050016877A (ko) | 알부민 정제 방법 | |
| JPS59169490A (ja) | 酸性プロテア−ゼの採取法 | |
| TH32720A (th) | กรรมวิธีสำหรับการผลิตของ rDSPA ?1 | |
| TH33047B (th) | กรรมวิธีสำหรับการผลิตของ rDSPA ?1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090225 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |